We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Influence of Patient Sex on Pain Control and Multimodal Analgesia in Total Knee Arthroplasty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04471233
Recruitment Status : Recruiting
First Posted : July 15, 2020
Last Update Posted : July 18, 2022
Sponsor:
Information provided by (Responsible Party):
Northwell Health

Brief Summary:
The purpose of this study is to examine the influence of sex on postoperative pain, following total knee arthroplasty (TKA). Patients will first be stratified by sex and then be randomized into one of two multimodal analgesic regimen (MAR), which differ in presence of pregabalin. We hypothesize that that acute postoperative pain scores are different over time between males and females and between multimodal analgesic regimens following TKA. Investigators will be blinded to which multimodal group patients are in. Patients will complete surveys in the office, during their hospital stay, and at followup intervals for up to six months.

Condition or disease Intervention/treatment Phase
Knee Osteoarthritis Pain, Postoperative Other: Multimodal analgesia including pregabalin Other: Multimodal analgesia not including pregabalin Phase 4

Detailed Description:

The overall goal of this study is to better understand the influence of patient-sex on postoperative pain perception in men versus women following total knee arthroplasty (TKA) utilizing two different multimodal analgesia regimens.

Pregabalin is a neuromuscular antagonist of voltage gated calcium channels at the post-synaptic dorsal horns in the spinal cord and brain. It binds to the alpha-2-delta subunit and interrupts pain signal transmission. The use of pregabalin as part of multimodal pain control has been associated with a decrease in postoperative opioid use.

This will be a randomized, single-blinded control trial in which patients either will or will not receive pregabalin as part of their multimodal analgesia regimen following TKA. It will be performed at a single institution, with multiple tertiary academic centers.

Patients will first be grouped according to their sex, then randomized into one of two arms:

  1. Multimodal analgesia regimen including pregabalin;
  2. Multimodal analgesia regimen not including pregabalin.

For the intervention group, patient will be provided with an oral preoperative pregabalin dose of 150mg on the day of surgery. Patient will continue pregabalin 75mg two times a day, for two weeks postoperatively. For both both groups, the operative technique and additional perioperative analgesic modalities will follow a standard protocol.

Primary Endpoint: Acute postoperative pain difference (up to 72 hours), measured by 100mm visual analogue scale (VAS) while at rest and mobilization, between males and females and between multimodal analgesic regimens in patients undergoing TKA.

Secondary Endpoints:

  • Pain control measured by 100mm visual analogue scale (VAS) while at rest and mobilization.
  • Pain control additionally measured by morphine equivalent units (MEq).
  • Number of postoperative days to opioid cessation.
  • Pain measured by Knee Injury and Osteoarthritis Outcome Score (KOOS).
  • Physical function measured by KOOS, physical component summary (PCS-12) of VR-12.
  • Mental health measured by mental component summary (MCS-12) of VR-12.
  • Safety will be tracked by adverse reactions reported or observed by investigators. These will be collected via patient communication and review of the medical record.
  • Additionally, severity of common short-term postoperative complications like nausea, vomiting, dizziness, and sedation will be assessed by 100mm VAS.

The study recruitment phase is estimated to last for 6 months. Subject followup is 6 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Intervention is preoperative and 14 days postoperatively. Patients will be assigned to either multimodal analgesia regimen. No crossing over of patients will occur.
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Masking Description: Care providers, and investigators will all be blinded to patient group identity.
Primary Purpose: Treatment
Official Title: Influence of Patient Sex on Pain Control and Multimodal Analgesia in Total Knee Arthroplasty
Actual Study Start Date : December 9, 2020
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : March 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Pregabalin

Arm Intervention/treatment
Experimental: Multimodal analgesia regimen including pregabalin
For the pregabalin group, patient will be provided with an oral preoperative pregabalin dose of 150mg on the day of surgery. Patient will continue pregabalin 75mg two times a day, for two weeks postoperatively. For both the intervention and control groups, the operative technique and additional perioperative analgesic modalities will follow a standard protocol
Other: Multimodal analgesia including pregabalin
Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal. Patient will be provided with an preoperative pregabalin dose and will continue medication two weeks postoperatively.

Active Comparator: Multimodal analgesia regimen not including pregabalin
For the non-pregabalin group, patient will be undergo total knee arthroplasty with the same operative technique and additional perioperative analgesic modalities will follow a standard protocol
Other: Multimodal analgesia not including pregabalin
Standardized protocol for our institution with multiple medications used for pain (NSAIDs, opioids, dexamethasone) and non-narcotic spinal.




Primary Outcome Measures :
  1. Assess influence of sex and multimodal analgesia regimens on acute postoperative pain scores at 48 hours postoperatively, in patients undergoing TKA. [ Time Frame: 48 hours ]
    Pain control measured by 100mm visual analogue scale (VAS) while at rest 48 hours after the procedure.


Secondary Outcome Measures :
  1. Assess how sex differences and multimodal analgesia regimens influence physical function [ Time Frame: 26 weeks ]
    -Pain measured by Knee Injury and Osteoarthritis Outcome Score (KOOS) of week 4, week 12, week 26 postoperatively, compared to baseline.

  2. Assess how sex differences and multimodal analgesia regimens influence postoperative narcotic medication use [ Time Frame: 72 hours ]
    Pain control additionally measured by morphine equivalent units (MEq) for 24, 48, and 72 hours after the end of the procedure.

  3. Assess how sex differences and multimodal analgesia regimens influence postoperative narcotic medication cessation [ Time Frame: 2 weeks ]
    -Number of postoperative days to opioid cessation.

  4. Assess how sex differences and multimodal analgesia regimens influence chronic postoperative pain [ Time Frame: 26 weeks ]
    -Chronic: Pain control measured by 100mm visual analogue scale (VAS) (0 corresponding to no pain and 100 corresponding to worst possible pain) while at rest and mobilization at week 1, week 2, week 4-6, week 12, week 26 postoperatively.

  5. Assess how sex differences and multimodal analgesia regimens influence mental health [ Time Frame: week 26 ]
    -Mental health measured by mental component summary (MCS-12) of VR-12 of week 2, week 4, week 12, week 26 postoperatively, compared to baseline.

  6. Assess how sex differences and multimodal analgesia regimens influence physical function [ Time Frame: 26 weeks ]
    -Physical function measured physical component summary (PCS-12) of Veterans Rand-12 (VR-12) at week 2, week 4, week 12, week 26 postoperatively, compared to baseline.

  7. Assess how sex differences and multimodal analgesia regimens influence range of motion (ROM) [ Time Frame: 26 weeks ]
    Range of Motion (ROM) of week 2, week 4, week 12, week 26 postoperatively, compared to baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Eligibility will be based on biological sex
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of signed and dated informed consent form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, age 18-80
  4. Undergoing primary unilateral TKA for primary osteoarthritis
  5. English speaking
  6. Patients whose primary residence is in a home and not a facility or rehabilitation center.

Exclusion Criteria:

  1. Chronic (>6 months) use of neuromodulators pregabalin or gabapentin.
  2. Pregnancy or lactation
  3. Prior history of adverse reactions to pregabalin
  4. Coexisting chronic pain condition rated ≥50mm on 100-mm VAS requiring narcotics.
  5. Coexisting condition leading to sedation or dizziness
  6. Kidney disease
  7. History of angioedema
  8. History of depression with suicidal ideation.
  9. Extensive history of opioid/ substance use and/or abuse.
  10. Receiving active or maintenance treatment for cancer or solid organ and/or marrow transplant.
  11. Patient staying less than one night in the hospital.
  12. Patients with a history of chronic obstructive pulmonary disease (COPD) with supplementary oxygen requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04471233


Contacts
Layout table for location contacts
Contact: Caroline Aprigliano 5166400317 caprigliano@northwell.edu

Locations
Layout table for location information
United States, New York
Northwell Health Orthopedic Institute at Great Neck Recruiting
Great Neck, New York, United States, 11021
Contact: Cesar Iturriaga    718-470-7320    citurriaga@northwell.edu   
Sponsors and Collaborators
Northwell Health
Investigators
Layout table for investigator information
Principal Investigator: Jonathan Danoff, MD Northwell Health
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: Northwell Health
ClinicalTrials.gov Identifier: NCT04471233    
Other Study ID Numbers: 20-0139
First Posted: July 15, 2020    Key Record Dates
Last Update Posted: July 18, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Pain, Postoperative
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Postoperative Complications
Pathologic Processes
Pain
Neurologic Manifestations
Pregabalin
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anticonvulsants
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs